$27.2B
$768,000
0.03% of portfolio
15,784
Q1 2024
Reduced 39.58%
$14.4B
$691,000
0.03% of portfolio
1,840
Q3 2024
Reduced 90.36%
$376B
$657,000
0.03% of portfolio
3,800
Q3 2017
New
$44.8B
$834,000
0.03% of portfolio
2,800
Q3 2024
Reduced 41.67%
$10.9B
$417,000
0.02% of portfolio
3,340
Q3 2024
Reduced 10.7%
$93B
$540,000
0.02% of portfolio
4,140
Q3 2024
Reduced 66.56%
$50B
$401,000
0.02% of portfolio
1,240
Q2 2023
Reduced 43.12%
$54.8B
$449,000
0.02% of portfolio
3,420
Q2 2024
Reduced 45.37%
$49B
$436,000
0.02% of portfolio
3,230
Q3 2024
Reduced 92.85%
$103B
$516,000
0.02% of portfolio
3,400
Q2 2024
Reduced 86.58%
$37.1B
$569,000
0.02% of portfolio
5,774
Q1 2023
Added 49.97%
$113B
$446,000
0.02% of portfolio
5,332
Q2 2022
Reduced 39.75%
$185B
$504,000
0.02% of portfolio
1,290
Q2 2023
Reduced 50.19%
$10.9B
$346,000
0.01% of portfolio
1,040
Q3 2024
Reduced 95.77%
$75.2B
$201,000
0.01% of portfolio
770
Q3 2017
New
$15.7B
$253,000
0.01% of portfolio
650
Q3 2024
Reduced 96.04%
$16.6B
$250,000
0.01% of portfolio
890
Q3 2024
Reduced 72.87%
$136B
$298,000
0.01% of portfolio
900
Q3 2024
Reduced 97.65%
$10B
$280,000
0.01% of portfolio
3,570
Q2 2023
Reduced 59.06%
$0
$142,000
0.01% of portfolio
500
Q4 2018
New
$41B
$247,000
0.01% of portfolio
3,460
Q3 2019
Reduced 94.91%
$70.4B
$273,000
0.01% of portfolio
1,000
Q1 2019
Reduced 98.45%
$17.4B
$134,000
0.01% of portfolio
2,160
Q3 2019
Reduced 97.53%
$138B
$240,000
0.01% of portfolio
3,844
Q3 2024
Reduced 97.51%
$6.32B
$255,000
0.01% of portfolio
8,620
Q3 2024
Reduced 91.42%
$9.43B
$337,000
0.01% of portfolio
2,150
Q3 2024
Reduced 36.2%
$79.5B
$250,000
0.01% of portfolio
2,000
Q4 2020
Reduced 22.48%
$55.7B
$227,000
0.01% of portfolio
4,550
Q3 2024
Reduced 98.6%
$264B
$244,000
0.01% of portfolio
3,397
Q1 2022
Reduced 50.19%
$138B
$122,000
0.01% of portfolio
340
Q3 2024
Reduced 99.72%
$10.7B
$268,000
0.01% of portfolio
1,630
Q3 2024
New
$1.52B
$163,000
0.01% of portfolio
5,910
Q2 2023
Reduced 61.52%
$150B
$188,000
0.01% of portfolio
6,500
Q3 2017
New
$95.4B
$197,000
0.01% of portfolio
2,780
Q1 2024
Reduced 97.88%
$19.3B
$163,000
0.01% of portfolio
3,250
Q3 2024
Reduced 77.1%
$54.8B
$220,000
0.01% of portfolio
5,260
Q3 2024
Reduced 98.6%
$5.17B
$339,000
0.01% of portfolio
10,060
Q3 2024
Reduced 80.59%
$89.7B
$176,000
0.01% of portfolio
2,000
Q3 2023
Reduced 99.57%
$132B
$131,000
0.01% of portfolio
1,560
Q2 2023
Reduced 50.16%
$9.58B
$214,000
0.01% of portfolio
2,070
Q3 2024
Reduced 96.41%
$123B
$201,000
0.01% of portfolio
3,240
Q2 2023
Reduced 50.0%
$107B
$43,000
0.0% of portfolio
480
Q4 2019
Reduced 99.84%
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 14.47%
Kiniksa Pharmaceuticals Intl
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
New
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 29.98%
$78.6B
$51,000
0.0% of portfolio
2,200
Q1 2018
Reduced 99.61%
$764M
$25,000
0.0% of portfolio
1,150
Q3 2019
Reduced 96.1%
-
$0
0.0% of portfolio
-
Q3 2024
Reduced 3.52%
$15.6B
$70,000
0.0% of portfolio
580
Q4 2020
Reduced 98.14%